• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

AstraZeneca Forms Health Tech Business, Evinova to Deliver Digital Health Solutions for Life Sciences

Share:

November 27, 2023

AstraZeneca, a global biopharmaceutical company, has launched Evinova, a new venture focused on pioneering digital health solutions for healthcare professionals, regulators, and patients. Backed by AstraZeneca’s support and partnerships with Parexel and Fortrea, Evinova aims to lead in globally-scaled digital offerings for life sciences. Initially concentrating on proven digital solutions for clinical trials, it plans to expand into remote patient monitoring and digital therapeutics. Collaborating with Parexel, Fortrea, Accenture, and Amazon Web Services, Evinova strives to revolutionize medicine development, enhance patient care, and drive healthcare transformation through cutting-edge digital technologies. CEO Pascal Soriot anticipates these innovations will significantly improve healthcare while reducing carbon emissions.

AstraZeneca, a global biopharmaceutical company, has announced the launch of Evinova, a new business venture dedicated to providing cutting-edge digital health solutions that address the evolving needs of healthcare professionals, regulators, and patients.

With long-term support from AstraZeneca and strategic partnerships with Parexel and Fortrea, Evinova aims to become a leading provider of globally-scaled digital products and services for the life sciences and healthcare sector.

Digital Solutions for Clinical Trials

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Evinova’s initial focus will be on bringing established and scaled digital technology solutions to market, leveraging AstraZeneca’s proven expertise in optimizing clinical trial design and delivery. These solutions have already demonstrated their effectiveness in reducing the time and cost of developing new medicines, bringing care closer to home for patients, and alleviating the burden on healthcare systems.

Expansion into Remote Patient Monitoring and Digital Therapeutics

Evinova will also pursue opportunities in digital remote patient monitoring and digital therapeutics, with a pipeline of innovative solutions in these areas. Drawing on AstraZeneca’s deep experience in developing novel therapeutics and insights from thousands of patients and clinical researchers, Evinova will provide established technology solutions to pharma, biotech, and CROs to support clinical research globally.

Partnership with Parexel and Fortrea

Evinova’s success is built on collaboration. Globally leading CROs Parexel and Fortrea have entered into agreements to offer Evinova’s digital health solutions to their extensive customer base. Additionally, Evinova is partnering with Accenture and Amazon Web Services to accelerate industry adoption and expand the global reach of its digital products.

Pascal Soriot, Chief Executive Officer of AstraZeneca, expressed his optimism about the future of medicine and the role of digital solutions. He stated, “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale provides a real opportunity to fundamentally improve patient care, drive healthcare transformation, and reduce carbon emissions.”

Source: Hitconsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Biogen, Eisai’s anti-amyloid drug slows Alzheimer’s decline, but debate rages onBiogen, Eisai’s anti-amyloid drug slows Alzheimer’s decline, but debate rages on
  • IDEX Corporation’s Capital Deployment Continues with Agreement to Acquire Muon Group, a Leader in Precision Tech Manufacturing, for €700 Million
  • Konica Minolta and Shimadzu Join Forces to Bring Dynamic Digital Radiography to the US Digital Radiography MarketKonica Minolta and Shimadzu Join Forces to Bring Dynamic Digital Radiography to the US Digital Radiography Market
  • Ergomed strongly positioned for future growth in new partnership with PermiraErgomed strongly positioned for future growth in new partnership with Permira
  • Amgen Completes Acquisition of Otezla® (Apremilast)Amgen Completes Acquisition of Otezla® (Apremilast)
  • ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBioACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio
  • Amazon Care Goes Live for Its Seattle-Based EmployeesAmazon Care Goes Live for Its Seattle-Based Employees
  • Hillrom Announces Acquisition Of Breathe TechnologiesHillrom Announces Acquisition Of Breathe Technologies

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications